Level C· Early human research exploring benefitsProspective StudyPubMed

Assessing "Cell Therapy" Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States.

Nirwan RS., Albini TA., Sridhar J., Flynn HW., Kuriyan AE.

Prospective Study on Systemic / IV, published in Ophthalmology (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Ophthalmology (2019)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
30904542
PMCID
PMC6754792
DOI
10.1016/j.ophtha.2019.03.019
Citations
27

Abstract (original English)

Purpose "Cell therapy" is becoming increasingly available to the public via online direct-to-consumer advertisement within the United States (U.S.). The current study investigates the scope of "cell therapy" clinics across the U.S. that advertise and offer "cell therapy" for ocular conditions based on information provided on their websites. Design Cross-sectional study. Participants The study included companies that are U.S.-based, participate in direct-to-consumer online marketing, have websites that can be data-mined with content analysis, and advertise therapy for ocular conditions. Methods Using a systematic, extensive keyword-based Internet search, content analysis of company websites was utilized to identify, document, and analyze U.S. businesses marketing "cell therapy" for ocular conditions as of September 16, 2017. Main outcome measures Clinic locations, source of stem cells used, route of administration, marketed ocular conditions, and cost of treatment. Results Forty companies with 76 clinics use "cell therapy" to treat ocular conditions. California (23), Florida (12), and Illinois (10) contain the most clinics. All 40 companies specified sources of cells, which included autologous adipose-derived stem cells (35; 67%), autologous bone marrow-derived stem cells (8; 15%), amniotic stem cells (2; 4%), peripheral blood-derived stem cells (2; 4%), umbilical cord blood ste

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Ambulatory Care FacilitiesCell- and Tissue-Based TherapyCross-Sectional StudiesDirect-to-Consumer AdvertisingEye DiseasesHumansInternetUnited States

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research